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Abstract
Background: Recombinant proteins of therapeutic use are ideally produced in human cells to ensure appropriate
co- and post-translational modifications. However, purification of secreted proteins from the culture media is
impeded by low expression from transfected cell lines and the presence of serum proteins. Here we describe a
simple and cost-effective approach based on lentiviral vector-mediated gene delivery and expression of a secreted
His-tagged protein from human embryonic kidney 293 T cells and direct affinity chromatography purification from
the cell culture media.
Results: Using a protein-based HIV entry inhibitor, soluble CD4 (sCD4), we demonstrated that 293 T cells
transduced with a lentiviral vector mediated over 10-fold higher secretion of sCD4 in comparison to 293 T cells
transfected with the corresponding plasmid. Secretion of sCD4 increased with the dose of the lentiviral vector up
to a multiplicity of infection of 50. Exchanging the native signal peptide of sCD4 with the signal peptide of human
alpha-1 antitrypsin increased expression by 50 %. There was no difference in expression from a monocistronic or
bicistronic lentiviral vector. Reduction of the serum concentration in the culture media had no significant effect on
the secretion of sCD4. Small-scale purification from 50 ml of culture media with reduced serum content yielded
up to 1 mg of pure sCD4. Purified sCD4 bound to recombinant HIV envelope glycoprotein 120 (Env gp120) and
inhibited HIV entry at concentrations comparable to published results.
Conclusion: The procedure outlined in this study can be performed without the need for specialized reagents or
equipment and could easily be adapted by any laboratory. Furthermore, the method could be used to produce
sCD4 fusion proteins or other His-tagged proteins.
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Background
Expression systems based on bacteria, yeast, insect cells
and plants have successfully been used to express re-
combinant proteins at high levels. Each system has its
own advantages, but none can fully recapitulate the ex-
tensive co- and post-translational modifications found in
some human proteins [1–4]. In order to ensure func-
tionality and to be as close as possible to their native
state, many human proteins are now produced in Chin-
ese hamster ovary (CHO) cells and human embryonic
kidney (HEK) cells. Both cell lines are well established
and have been utilized to produce clinically relevant pro-
teins [5]. While both CHO and HEK cells are capable of
extensive glycosylations, it has recently become more
and more evident that proteins produced in CHO cells
have a different glycosylation pattern than the same pro-
teins produced in HEK cells, which may affect their
function [6–10]. For example, a fusion protein containing
the extracellular domain of the human interleukin-23 re-
ceptor and a crystalizing fragment (Fc) region produced in
HEK cells was less stable in mice than the same protein
produced in CHO cells [6]. In another study, an Fc recep-
tor (CD16) produced in HEK cells exhibited slower anti-
body binding and dissociation kinetics in comparison to
CD16 from CHO cells [7]. While the exact implications of
differences in glycosylation are not yet fully understood, a
strong argument for the production of therapeutic pro-
teins in HEK cells is made by the finding that CHO cells
can add terminal galactose-α-1,3-galactose (α-Gal) to pro-
teins [11, 12]. α-Gal is a non-human antigenic glycan and
its reaction with circulating antibodies present in most
individuals can lead to anaphylaxis [11, 13]. This glycan is
absent in proteins produced in HEK cells [14].
Production of secreted proteins in human cells is
usually achieved by large-scale transient transfections to
compensate for low expression levels. However, repeated
large-scale transfections require high quantities of a
transfection reagents and plasmid DNAs. Highly effi-
cient transfection systems with specialized reagents and
cell lines are available, but are commonly substituted
with polyethylenimine (PEI) transfection of HEK cells to
reduce the cost [15–17]. An alternative to transient
transfection is the generation of stable clonal cell lines
[18]. Stable chromosomal integration and expression
from transfected DNA relies on coupling protein expres-
sion to a selectable marker. Since transgene expression
varies depending on the integration site, different clones
are isolated by limiting dilution and tested for transgene
expression, which is tedious. Transduction with lentiviral
vectors is another method of generating stable cell lines.
Cells transduced with lentiviral vectors have been used
to express secreted proteins [19, 20]. However, the lentiviral
vector backbones used in these studies were custom made
and are not readily available. Furthermore, production and
titration of these vectors required specific cell lines, media,
and lengthy concentration procedures [19, 20]. Regardless
of the expression system, the recombinant proteins are
usually purified from ≥1 l cell culture supernatants. Since
standard culture media contain high amounts of serum
proteins that can interfere with the purification process or
contaminate the final protein preparations [21], serum
proteins are removed prior to protein purification or spe-
cialized serum-free media is used.
In order to facilitate the purification process, the protein
of interest is usually fused to a protein tag (e.g. human
influenza hemagglutinin). Immobilized antibodies directed
against the protein tag are commonly used to isolate the
protein of interest from the culture media [15].
Here we describe a simple and effective method for
the purification of a His-tagged human protein from the
culture media of lentiviral vector-transduced HEK 293 T
cells. All reagents are readily available at a relatively low
cost and no specialized equipment is needed to complete
the procedure. Using soluble CD4 (sCD4), a truncated
version of the CD4 receptor that is secreted, we were
able to purify up to 1 mg of the protein from small-scale
cell cultures. The expression system and the purification
method used here can easily be adapted for purification
of other proteins by most laboratories.
Methods
Cells, plasmids and proteins
HEK 293 T cells were obtained from Dr. Jason Moffat
(University of Toronto, Toronto, Canada). 293 T and
TZM-bl cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Thermo Fisher Scientific,
Waltham, United States) supplemented with 10 % fetal
bovine serum (FBS, Thermo Fisher Scientific) and 1 %
Antibiotic-Antimycotic (Thermo Fisher Scientific). The
self-inactivating bicistronic lentiviral vector pLV-CMV
was constructed by replacing the PstI-to-NheI fragment
of pLVX-IRES-ZsGreen1 (Clontech, Mountain View
California, United States) with the compatible NsiI-to-
AvrII fragment from pLJM1-EGFP [22]. The monocistro-
nic vector pLV-CMV-M was generated by deleting the
SacII fragment of pLV-CMV. The gene encoding sCD4
(amino acids 1-209 of CD4, UniProtKB P01730, followed
by GGGSGAGCCPGCC HHHHHH) and the different
signal peptides were synthesized and sequenced by Gen-
script (Piscataway, United States). The gene encoding
sCD4 was preceded by an EcoRI site and followed by a
NotI site and cloned as an EcoRI-to-NotI fragment into
the multiple cloning site of the bicistronic lentiviral vec-
tor pLV-CMV to generate pLV-CMV-sCD4. The nucleo-
tide sequence of the signal peptides was flanked by an
EcoRI site at the 5’ end and nucleotides 76-218 of the
open reading frame of sCD4 containing an ApaI site at
the 3’ end. The EcoRI-to-ApaI fragments containing the
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different signal peptide sequences were each used in tri-
partite ligation reactions with the ApaI-to-BamHI and
BamHI-to-EcoRI fragments of pLV-CMV-sCD4 to gen-
erate pLV-CMV-AAT-sCD4, pLV-CMV-TPA-sCD4 and
pLV-CMV-IgG-sCD4. The AAT-sCD4 gene was trans-
ferred from pLV-CMV-AAT-sCD4 as an NdeI-to-NotI
fragment to the corresponding sites of the monocistronic
vector pLV-CMV-M to generate pLV-CMV-M-AAT-sCD4.
The pJRFL-env and pHXB2-env plasmids expressing HIV
Env gp160 from HIVJRFL and HIVHXB2, respectively, were a
kind gift from Dr. Donald Branch (University of Toronto).
The following reagents were obtained through the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH:
psPAX2 and pMD2.G from Dr. Didier Trono; TZM-bl and
pSG3Δenv from Drs. John C. Kappes and Xiaoyun Wu
[23–28]; sCD4-183 from Pharmacia Inc. [29]; and HIVBaL
gp120.
Production and titration of lentiviral vector particles
On day one, 7 × 106 293 T cells were seeded into a
10 cm cell culture dish in 9 ml culture media. 24 h later,
the media were replaced with 9 ml fresh media. 1.5 h
later, chloroquine (Bioshop, Burlington, Canada) was
added at a final concentration of 25 μM. 10.5 μg of the
lentiviral vector construct, 7 μg of psPAX2 and 3.5 μg of
pMD2.G were added to a 1.5 ml tube in a final volume
of 450 μl. 50 μl of 2.5 M calcium chloride were added
dropwise and the tube was vortexed for a short time.
After 5 min, 500 μl of 2xHBS (50 mM HEPES, 1.5 mM
disodium hydrogen phosphate, 280 mM sodium chlor-
ide, 10 mM potassium chloride, and 12 mM sucrose)
were added dropwise to form calcium phosphate-DNA
precipitate. After vortexing the tube for a short period,
the mixture was incubated for 1 min and added drop-
wise to the cells. The next day, media were exchanged
with 10 ml fresh media and the cells were incubated for
48 h. Culture supernatants were harvested, filtered
(0.45 μm pore size), aliquotted and stored at -80 °C. To
determine the titer, 2 × 105 293 T cells were mixed with
serial dilutions of the vector particles in the presence of
polybrene (final concentration 8 μg/ml; Sigma Aldrich,
Missouri, Unites States) in a 12-well plate in a final vol-
ume of 1 ml. The percentage of cells that emitted green
fluorescence was determined by flow cytometry or fluor-
escence microscopy after 3 days.
Transfection and transduction of 293 T cells
For transfection, 7×105 293 T cells per well were cul-
tured in 1 ml culture media in a 12-well plate for 1 day.
Media were exchanged and 1 h later each well was
transfected with 0.75 μg of pLV-CMV-AAT-sCD4 using
PolyJet transfection reagent (FroggaBio, North York,
Canada) according to the manufacturer’s instructions.
For transduction, 1×105 293 T cells were mixed with the
lentiviral vector at the indicated multiplicity of infection
(MOI) and polybrene (final concentration 8 μg/ml) in a
12-well plate in a 1 ml volume. The cells were incubated
for 3–4 days. The cells were sub-cultured for 1–2 weeks
and then used in subsequent experiments.
PCR
Genomic DNA was extracted using the PureLink gDNA
mini kit (Thermo Fisher Scientific) according to the
manufacturer’s instructions. The primer sequences for
the detection of integrated vector were A005-F 5’-TCTG
TAGCGACCCTTTGCAG-3’ and A005-R 5’-CACGCC
GTAGAACTTGGACT-3’. The primer sequences for the
detection of genomic ß-actin were A006-F 5’-CAGC
AAGCAGGAGTATGACGA-3’ and A006-R 5’- CACTC
TGGGTAAG GACAAGTTGG-3’. The primers were
synthesized by ACGT DNA Technologies Corporation
(Toronto, Canada). PCRs were set up using 2X Taq
FroggaMix (Froggabio), 0.5 μg genomic DNA, and
1.5 μM forward and reverse primers. The cycles were: 1)
94 °C for 10 min; 2) 94 °C for 0.5 min; 3) 60 °C for
0.5 min; 4) 72 °C for 0.5 min; and 5) 72 °C for 10 min.
Cycles 2–4 were repeated 24 times.
Detection and purification of His-tagged proteins
Culture media were clarified by short centrifugation at
low speed. His-tagged proteins in the culture media were
detected using a competitive Enzyme-linked immu-
nosorbent assay (ELISA; Genscript) according to the
manufacturer’s instructions. Briefly, culture media and a
mouse anti-His-tag mAb were added to wells coated
with a His-tagged protein. The wells were washed and
bound mAb was detected with an horseradish peroxid-
ase (HRP)-conjugated goat anti-mouse IgG. Following
additional washes, HRP activity was visualized using
3,3′,5,5′-tetramethylbenzidine substrate and the reaction
was stopped. SDS-PAGE, Coomassie blue staining, and
Western blot analyses were performed as described pre-
viously [30, 31]. Some gels were stained using One-Step
Blue Protein Gel Stain (Biotium, Hayward, United
States). For purification, a HisTalon cobalt gravity col-
umn (Clontech) was equilibrated with 10 ml equilibra-
tion buffer (50 mM sodium phosphate, 300 mM sodium
chloride; pH 7.4). 50 ml of the clarified culture media
were directly applied to the column at room tempe-
rature. The column was washed with 8 ml equilibration
buffer and 7 ml wash buffer (50 mM sodium phosphate,
300 mM sodium chloride, 10 mM imidazole; pH 7.4).
The proteins were eluted with 4 ml elution buffer
(50 mM sodium phosphate, 300 mM sodium chloride,
and 150 mM imidazole; pH 7.4) in 3 fractions (first frac-
tion, 1 ml; second fraction 1.5 ml; and third fraction
1.5 ml). The second fraction contained the majority of
the protein and was applied to a 5 ml Zeba spin column
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with 7 K MWCO (Thermo Fisher Scientific) to exchange
the elution buffer with PBS.
HIV gp120 binding assay
Purified HIVBaL gp120 (2 μg/ml; 100 μl per well) was
diluted in 0.05 M sodium carbonate buffer, pH 9.6 and
coated onto untreated 96-wells overnight at 4 °C. Un-
coated wells served as a control. Wells were washed 4
times with PBS containing 0.05 % Tween 20 (Sigma),
blocked with PBS containing 5 % bovine serum albumin
fraction V (BSA, Bioshop) for 2 h at room temperature,
followed by 4 washes. 50 μl of sCD4 diluted in PBS con-
taining 0.1 % BSA and 0.05 % Tween 20 were added to
all wells at the indicated concentrations and incubated
overnight at 4 °C. Wells were washed 4 times and incu-
bated with 50 μl of a ready-to-use mouse anti-His-tag
monoclonal antibody solution (Genscript) for 1 h at
room temperature. After 4 additional washes, 100 μl of a
ready-to-use HRP-conjugated goat anti-mouse IgG solu-
tion (Genscript) were added to each well and the plates
were incubated for 30 min. After 4 washes, 100 μl of
3,3',5,5'-Tetramethylbenzidine substrate (Genscript) were
added for 5 min and the reaction was stopped by adding
Stop Solution (Genscript). The OD at 450 nm was deter-
mined using a standard plate reader and background
values obtained for control wells were subtracted.
Antiviral assay
Replication-incompetent virus was generated by trans-
fecting 293 T cells with 10.5 μg of pSG3Δenv encoding
the HIV genome with a deletion in the HIV Env gp160
open reading frame and 10.5 μg of an HIV Env gp160-
encoding plasmid (pHXB2-env, pJRFL-env or pMD2.G)
using the calcium phosphate transfection method de-
scribed above for lentiviral vector particle production.
The 50 % tissue culture infectious dose (TCID50) and
inhibition of HIV entry were determined in TZM-bl
cells, which express the lacZ gene under the control of
the HIV long terminal repeat promoter. Virus (5×103
TCID50) was mixed with sCD4 at the indicated concen-
tration and added to 5 × 104 TZM-bl cells together with
polybrene (8 μg/ml final concentration) in 24-well plates.
The cells were incubated for 2 days, fixed with 1 % for-
maldehyde for 5 min, and stained with X-Gal (0.4 mM
potassium ferricyanide, 0.4 mM potassium ferrocyanide,
20 mM magnesium chloride, 0.4 μg/ml X-Gal) overnight
at room temperature. Three random microscope images
were taken for each well and infected (blue) cells were
counted.
Statistical analysis
Data are presented as means +/− standard error of the
mean. Where appropriate, unpaired t test was used to
test for statistical difference between two groups.
Results and discussion
Lentiviral vector expressing sCD4 and transduction of
HEK 293 T cells
sCD4 mimics the natural CD4 receptor that is necessary
for HIV entry into target cells. The secreted protein is
the first HIV entry inhibitor described in the literature
[32]. Administration of high doses of sCD4 produced in
CHO cells has been shown to reduce viral load in two
small clinical trials [33, 34]. However, frequent injections
of highly purified proteins were not feasible for the long-
term treatment of HIV-infected individuals. Currently,
sCD4 is used in countless studies examining the mech-
anism and inhibition of HIV entry. The open reading
frame of the sCD4 gene used in this study is comprised
of the native signal peptide and the first two domains of
CD4, which allow binding to the HIV Env gp120. The
second domain is followed by a 6xHis-tag. A schematic
of sCD4 is shown in Fig. 1a. While the His-tag may be
less effective than newer tags, it is one of the most
widely used tags and antibodies as well as resins for
affinity chromatography are available at a relatively low
cost.
We chose to express sCD4 in HEK 293 T cells because
of their human origin and availability in many laborator-
ies. We used a self-inactivating lentiviral vector, LV-
CMV-sCD4, to minimize activation of neighboring genes
[35]. The vector contained the human cytomegalovirus
immediate early (CMV) promoter and is highly active in
293 T cells [36]. The bicistronic mRNA transcribed from
this vector allows simultaneous expression of sCD4 and
the enhanced fluorescent reporter protein ZsGreen1
[37]. Additionally, the vector contained the woodchuck
hepatitis post-transcriptional regulatory element (WPRE),
which has been shown to increase both the titer and
transgene expression in conjunction with the CMV pro-
moter [38, 39]. Similar vectors are readily available at any
plasmid repository. A schematic of the vector is shown in
Fig. 1a.
Calcium phosphate transfection of 293 T cells resulted
in sufficiently high vector titers without the need for
further concentration of vector particles. 293 T cells
showed a vector dose-dependent increase in the expres-
sion of ZsGreen1. Both the percentage of transduced
cells and fluorescence intensity increased with higher
doses as shown by fluorescence microscopy and flow
cytometry (Fig. 1b and c, respectively). Simultaneously,
the concentration of sCD4 in the culture supernatant of
transduced 293 T cells increased with the vector dose
(Fig. 1d).
Utilizing heterologous signal peptides to increase
secretion
The signal peptide is responsible for directing proteins
to the secretory pathway. Altering the signal peptide
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sequence has previously been shown to increase secre-
tion for some proteins [40, 41]. We exchanged the nat-
ural signal peptide of sCD4 with three commonly used
signal peptides and analyzed the resulting amino acid se-
quences with the bioinformatics program SignalP, which
discriminates secreted from non-secreted proteins [42].
The signal peptides and their SignalP scores are depicted
in Fig. 2a. The highest score was obtained for sCD4 with
the alpha-1 antitrypsin (AAT) signal peptide. The score
for sCD4 with the immunoglobulin G kappa chain signal
peptide (IgG) was same as the score for sCD4 with the
native signal peptide. sCD4 with the signal peptide of
the tissue plasminogen activator (TPA) yielded the low-
est score. The sCD4 genes with the different signal pep-
tides were cloned into the lentiviral vector and the
resulting vectors were used to transduce 293 T cells. The
percentage of gene-modified cells was >90 % for all vec-
tors at a MOI of 2 (data not shown). The AAT signal
Fig. 1 Lentiviral transduction of HEK 293 T cells. a Schematic diagram of the sCD4 open reading frame and the bicistronic lentiviral vector used
in this study. LTR = long terminal repeat; Ψ = packaging signal; RRE = rev response element; cPPT = central polypurin tract; IRES = internal ribosome
entry site; ΔU3 LTR = LTR with a deletion in the U3 promoter/enhancer region. b-d 293 T cells were transduced with LV-CMV-sCD4 at the indicated
MOIs. 2 × 105 gene-modified 293 T cells were seeded in a 12-well plate in 1 ml media and grown for 4 days. The cells were trypsinized and analyzed
by (b) fluorescence microscopy and (c) flow cytometry. d Supernatants were collected, centrifuged, and analyzed by Western blot using
an anti-His-tag antibody. MFI = median fluorescence intensity. The results are representative of at least 2 independent experiments
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peptide mediated a 50 % increase in protein concentra-
tion, while the TPA signal peptide caused a decrease,
and the IgG signal peptide no significant change (Fig. 2b).
Semi-quantitative PCR analysis of genomic DNA from
these cells indicated that the observed differences in
sCD4 secretion levels were not due to varying copy
numbers of the integrated proviral vector DNA (Fig. 2b).
The protein concentration in the culture media seemed
to correlate with the predicted Signal P scores, e.g. the
sCD4 with the AAT signal peptides had the highest score
and was present at the highest concentration. Since the
AAT signal peptide mediated a significant increase
over the native CD4 signal peptide, all subsequent
experiments were performed with sCD4 containing
the AAT signal peptide.
HEK 293 T cells can be transduced at high MOIs
293 T cells are an easy to transduce cell line and close to
100 % transduction efficiency can be achieved at rela-
tively low MOIs. In order to determine the maximal vec-
tor dose that can be used, 293 T cells were transduced
with LV-CMV-AAT-sCD4 at MOIs ranging from 0.4 to
100. Although reduced cell viability was evident immedi-
ately after transduction at a MOI of 100, all cells recovered
after a week (data not shown). The sCD4 concentration in
the media increased up to a MOI of 50 (Fig. 3a). No
Fig. 2 Utilizing alternative signal peptides to optimize protein secretion. a The signal peptide prediction software SignalP was used to analyze
sCD4 with different signal peptide sequences. The C-score identifies the signal peptide cleavage site. The S-score distinguishes signal peptides
from the mature protein. The Y-score is a combination of the C- and S-scores. The signal peptides, their sequence, and their final score are
indicated. b 293 T cells were transduced with LV-CMV-sCD4 (CD4), LV-CMV-TPA-sCD4 (TPA), LV-CMV-AAT-sCD4 or LV-CMV-IgG-sCD4 (IgG) encoding
sCD4 with the indicated signal peptide at a MOI of 2. 2 × 105 gene-modified 293 T cells were seeded in a 12-well plate in 1 ml media and cultured for
4 days. Genomic DNA was extracted from the cells and examined for the presence of integrated vector by PCR with vector-specific primers. PCR with
β-actin primers was performed as a control for equal input DNA (left panel). Supernatants were collected, centrifuged, and analyzed by Western blot
using an anti-His-tag antibody (left panel) and His-tag ELISA (right panel). The results are representative of 2 independent experiments performed in
duplicates; *p < 0.05
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differences in cell growth or viability were evident in com-
parison to untransduced control cells (Fig. 3b). Therefore,
cells transduced at a MOI of 50 were used in the following
experiments.
Optimizing conditions for the purification of sCD4
Lentiviral vector design can significantly affect transgene
expression. For example, clear differences between
monocistronic and bicistronic lentiviral vectors have
been shown to exist between different cell types [43].
We generated a monocistronic vector, LV-CMV-M, by
removing the ZsGreen1 open reading frame from pLV-
CMV. The titer of the monocistronic vector encoding
sCD4 with the AAT signal peptide, LV-CMV-M-AAT-
sCD4, was determined using HIV p24 antigen ELISA
because it did not encode ZsGreen1. 293 T cells were
transduced at a p24 concentration equaling a MOI of 50
for the bicistronic vector encoding sCD4 with the AAT
signal peptide, LV-CMV-AAT-sCD4. When sCD4 ex-
pression from cells transduced with the mono- or bicis-
tronic vector was compared in parallel, no significant
difference in protein concentration in the culture media
was detected (Fig. 4a). This result showed that the bicis-
tronic vector design did not have a negative effect on
the expression of sCD4 under the tested conditions.
Consequently, a bicistronic vector was used in the fol-
lowing experiments. However, if larger transgenes are
used, a monocistronic vector may be used because the
titer of lentiviral vectors can drop with the increased
vector size.
Transient expression is commonly used to produce se-
creted proteins in mammalian cells. Using a commer-
cially available transfection reagent, we compared sCD4
expression from 293 T cells transfected with the plasmid
pLV-CMV-AAT-sCD4 to sCD4 expression from 293 T
cells transduced with the lentiviral vector LV-CMV-
AAT-sCD4. Transfected and transduced 293 T cells were
cultured under the same conditions. Importantly, the
sCD4 concentration in the culture supernatants from
transduced 293 T cells was over 10-fold higher than in
the supernatants from transfected 293 T cells (Fig. 4b).
This result indicated that expression of secreted proteins
from transduced cells was advantageous not only in
terms of convenience, but also protein yield.
Standard culture media contain high quantities of
serum proteins, which are undesirable for the purifica-
tion of recombinant proteins. In our experience, 293 T
cells can tolerate low levels of serum once they reach a
confluent monolayer. To examine if reducing the serum
concentration in standard media affects the concentra-
tion of secreted protein, transduced cells were grown to
confluence and fresh media with a 10-fold reduced
serum concentration were added. Figure 4c shows that
reducing the serum concentration did not negatively
affect sCD4 secretion. Accordingly, simply using stand-
ard culture media with reduced serum presents a cost-
effective approach to reduce potential contaminants.
In an experiment to evaluate the effect of incubation
time, cells were grown to confluence and reduced serum
media were added. Culture supernatants were collected
after 1-5 days of culture and then analyzed for the sCD4
concentration by ELISA and SDS-PAGE. ELISA results
showed that the sCD4 concentration was the highest
after 5 days of incubation (Fig. 4, left panel). However,
Coomassie blue staining of an SDS-PAG showed the
appearance of additional bands after 3 days, including
a band corresponding to a slightly higher molecular
weight protein than sCD4 (Fig. 4, right panel), which
could represent sCD4 with an uncleaved signal pep-
tide and indicate cell leakage of cellular proteins into
the culture media. Therefore, 2 days of incubation
after the media change were considered optimal for
sCD4 production. Nevertheless, the incubation time
could be increased, if the secreted protein is stable
and a higher yield is desired, albeit potentially at the
cost of purity.
Fig. 3 Human 293 T cells can be transduced at high MOIs. 293 T cells were transduced with LV-CMV-AAT-sCD4 at the indicated MOIs. 2 × 105
gene-modified 293 T cells were seeded in a 12-well plate in 1 ml media and cultured for 4 days. a Concentration of sCD4 in the culture
supernatants determined by His-tag ELISA. b Cell growth analyzed by microscopy and cell viability determined by MTT-assay. The results are
representative of at least 2 independent experiments
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Purification of sCD4
For affinity chromatography purification of the protein,
cells were grown in five 10 cm cell culture dishes. Cul-
ture supernatants (50 ml) from transduced cells grown
in reduced serum media were clarified by centrifugation
and directly applied to a cobalt column. His-tagged pro-
tein was eluted and desalted. The purified protein was
analyzed by SDS-PAGE, followed by Coomassie blue
staining. The final product contained sCD4 devoid of
any major contaminating bands (Fig. 5a). The concentra-
tion of purified sCD4 was 48 μg/ml, as determined by
ELISA. However, in preliminary HIV entry inhibition
assays, the antiviral activity of purified sCD4 was over
10-fold higher than expected based on previously pub-
lished results (data not shown). Consequently, we com-
pared our purified sCD4 to an sCD4 protein standard
with a known concentration. SDS-PAGE analysis showed
that the actual concentration was closer to 800 μg/ml,
about 16.5-fold higher than the ELISA result suggested
(Fig. 5b). Therefore, care should be taken if ELISA is
used to determine the protein concentration.
Purified sCD4 specifically inhibits HIV entry
The functionality of sCD4 was assessed in an HIV Env
gp120-binding assay and by inhibition of HIV entry
(Fig. 6). sCD4 bound to immobilized gp120 in a dose-
Fig. 4 Optimizing conditions for the purification of sCD4. a Monocistronic versus bicistronic vector design. Cells were transduced with the
bicistronic vector LV-CMV-AAT-sCD4 or the monocistronic vector LV-CMV-M-AAT-sCD4 at a MOI of 50. 2 × 105 gene-modified 293 T cells in 1 ml
media were plated in a 12-well plate and cultured for 4 days before culture supernatants were analyzed by ELISA. b Effect of stable versus
transient expression on sCD4 secretion levels. 7 × 105 untransduced 293 T cells or 293 T transduced with LV-CMV-AAT-sCD4 were plated in a
12-well plate in 1 ml media and cultured for 1 day. Media were replaced with fresh media and unmodified 293 T cells were transfected with
pLV-CMV-AAT-sCD4. On day 2 after plating, media were replaced with fresh media and the cells were cultured for 2 additional days before ELISA was
performed on culture supernatants; *p < 0.05. c Effect of reducing serum concentration. Gene-modified 293 T cells were cultured and analyzed as in
(b), but on day 2 after plating culture media were replaced with media with the indicated FBS concentration. d Effect of incubation time. Cells were
cultured as in (c). Media were replaced on day 2 after plating with media containing 1 % FBS and supernatants were analyzed at the indicated time
points by ELISA (left panel) or SDS-PAGE followed by Coomassie blue staining (right panel). All results are representative of 2 independent experiments
performed in duplicates
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Fig. 5 Affinity purification of sCD4. a SDS-PAGE analysis of purified sCD4. 7 × 106 gene-modified 293 T cells were seeded into five 10 cm dishes.
Media were exchanged to fresh media 1 day after plating. On the second day, media were replaced with 10 ml fresh media containing 1 % FBS
and the cells were incubated for 2 additional days before sCD4 was purified from the supernatants. Samples from unmodified cells (mock),
gene-modified cells (LV-sCD4) and purified sCD4 were analyzed by SDS-PAGE followed by Coomassie blue staining. b Comparison of purified
sCD4 to an sCD4 standard from the National Institutes of Health. Equal volumes of the standard and purified sCD4 were analyzed by SDS-PAGE
followed by Coomassie blue staining. Results are representative of 3 independent experiments
Fig. 6 Antiviral effect of purified sCD4. a Binding of sCD4 to gp120. b Inhibition of HIV entry. 5 × 104 TZM-bl cells were infected with replication-
incompetent virus pseudotyped with the indicated HIV Env (TCID50 of 5 × 103) in the presence of the indicated concentration of sCD4. On day 2
post-infection, β-galactosidase activity was determined by incubation with X-gal. For each sample, the number of infected cells was determined
by counting the blue cells from 3 random microscopy images. c Representative microscopy images of cells infected in the presence (16 μg/ml)
or absence of sCD4. The results are representative of 2 independent experiments
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dependent manner (Fig. 6a). Entry of HIV strains was
examined in a single-round infection assay. Replication-
incompetent HIV particles were pseudotyped with the
HIVHXB2 or HIVJRFL Env gps or the unrelated VSV-G.
Both HIV strains need CD4 as the primary receptor, but
HIVHXB2 utilizes CXCR4 as a co-receptor and HIVJRFL
uses CCR5 as a co-receptor. In contrast, VSV-G requires
the low-density lipoprotein receptor for entry. The pseu-
doviruses were mixed with sCD4 and added to the CD4
+CXCR4+CCR5+ TZM-bl cells, which express the lacZ
gene under control of the HIV Tat protein. On day 2
post-infection, cells were stained with a ß-galactosidase
substrate (X-Gal) to visualize infected cells. Infection by
both of the HIV strains was inhibited in a dose-
dependent manner, while VSV-G entry remained un-
affected (Fig. 5b). Consistent with the literature,
HIVHXB2 was more sensitive to inhibition by sCD4 than
HIVJRFL (Fig. 6b and Table 1). Figure 6c shows represen-
tative microscopy images of infected wells. The half
maximal inhibitory concentrations (IC50s) obtained in
our experiments were comparable to previously pub-
lished results (Table 1), confirming that concentrations
obtained by ELISA underestimated the actual protein
concentration.
The sCD4 concentrations of purified preparations as
determined by ELISA and the adjusted concentrations in
relation to an sCD4 standard are shown. The corre-
sponding IC50s are compared to IC50s from the Los
Alamos HIV Database (CATNAP, Compile, Analyze and
Tally NAb Panels; http://hiv.lanl.gov/catnap).
Conclusions
We have developed an efficient and easy-to-follow
method to produce high quantities of sCD4 from human
cells. 293 T cells can be transduced with lentiviral vec-
tors at high MOIs. The transduced 293 T cells can be
grown into a confluent monolayer and then be cultured
in media with reduced serum concentration, which is a
cost-effective solution to minimize serum protein con-
taminations in the purified protein preparations. De-
pending on the stability of the secreted protein, the cells
can be incubated for several days before culture super-
natants are harvested. Using cost-effective metal ion
affinity chromatography, we have demonstrated that
pure preparations of His-tagged protein can be obtained
in a one-step process. We have further shown that using
an alternative signal peptide could increase the protein
yield. Screening potential signal peptides with the freely
available software SignalP may be helpful to identify
promising test candidates, but the best signal peptides
would have to be experimentally determined for differ-
ent proteins. The procedure should easily be adaptable
for purifying other secreted proteins. For example, we
have used this method to successfully produce the single
chain antibody 17b in similar quantities as well as sCD4
fusion proteins, albeit at 3-fold lower concentrations.
This strategy can be adapted to a large-scale format
without significantly increasing the cost to further
improve the yield.
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